Significance of non‐presynaptic SPECT tracer methods in Parkinson's disease

Tropane‐related tracers for SPECT and PET scanning have shown their value in assessing the in vivo striatal presynaptic status of the dopaminergic neurotransmitter system in man. Previously, there were a few other tracers suggested to be useful in the study of in vivo brain biochemistry in humans, particularly in patients afflicted with Parkinson's disease (PD) or parkinsonian syndromes. We summarize the work concerning the two main tracers applied in that context using single photon emission tomography (SPECT) scanning in patients with PD: IBZM and HMPAO. IBZM binds specifically to striatal dopamine D2 receptors and HMPAO uptake is a measure of cerebral tissue perfusion. © 2003 Movement Disorder Society

[1]  P J Slomka,et al.  Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. Nadeau,et al.  Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Gerhard Ransmayr,et al.  Brain perfusion scintigraphy with99mTc-HMPAO or99mTc-ECD and123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease , 1997, European Journal of Nuclear Medicine.

[4]  K. Leenders,et al.  Comparison of 123I‐IBZM SPECT and 11C‐raclopride PET findings in patients with parkinsonism , 1994, Nuclear medicine communications.

[5]  A. Antonini,et al.  [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease , 1994, Neurology.

[6]  D. Neary,et al.  A 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease , 1997, Journal of Neurology.

[7]  A J Lees,et al.  HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[8]  S. Asenbaum,et al.  Dopamine D2 receptor imaging and measurement with SPECT. , 1993, Advances in neurology.

[9]  R. Coppola,et al.  Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  C D Marsden,et al.  Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls , 1995, Movement disorders : official journal of the Movement Disorder Society.

[11]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[12]  W. Oertel,et al.  [123]IBZM Binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[13]  W. Oertel,et al.  123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[14]  H J Testa,et al.  A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? , 1998, Journal of neurology, neurosurgery, and psychiatry.

[15]  D. Eidelberg,et al.  Functional brain networks in Parkinson's disease. , 2001, Parkinsonism & related disorders.

[16]  K. Tatsch,et al.  Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. Missimer,et al.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. , 1995, Archives of neurology.

[18]  J D Speelman,et al.  Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. , 1993, Archives of neurology.

[19]  L. Defebvre,et al.  Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R P Maguire,et al.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. , 1997, Brain : a journal of neurology.

[21]  T. Vogl,et al.  Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism , 1999, Neuroradiology.

[22]  Johannes Schwarz,et al.  Steele‐Richardson‐Olszewski‐Syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: 123IBZM SPECT and MRI study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[23]  Jong-Ling Fuh,et al.  Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization , 1993, European Journal of Nuclear Medicine.

[24]  M. Dam,et al.  Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study. , 1993, European neurology.

[25]  J. Rinne,et al.  Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[26]  N Hosten,et al.  Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  W. Poewe,et al.  123I‐β‐CIT and 123I‐IBZM‐SPECT scanning in levodopa‐naive Parkinson's disease , 1998 .

[28]  W. Poewe,et al.  Correlation of clinical response in apomorphine test with D2‐receptor status as demonstrated by 123I IBZM‐SPECT , 1993, Movement disorders : official journal of the Movement Disorder Society.

[29]  J. Dichgans,et al.  Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[30]  M. Egan,et al.  In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine , 1999, Psychiatry Research: Neuroimaging.

[31]  B. Toone,et al.  In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans , 2004, European Journal of Nuclear Medicine.

[32]  N. Verhoeff,et al.  Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Jan Booij,et al.  Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism , 1999, European Journal of Nuclear Medicine.

[34]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[35]  T. Gasser,et al.  123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.

[36]  Andreas Heinz,et al.  Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels , 1997, Psychiatry Research: Neuroimaging.

[37]  O. Schober,et al.  [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders]. , 1994, Nuklearmedizin. Nuclear medicine.